論文

査読有り 国際誌
2020年7月16日

Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus.

Auris, nasus, larynx
  • Satoshi Koyama
  • ,
  • Kazunori Fujiwara
  • ,
  • Tsuyoshi Morisaki
  • ,
  • Taihei Fujii
  • ,
  • Yosuke Nakamura
  • ,
  • Takahiro Fukuhara
  • ,
  • Hiromi Takeuchi

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.anl.2020.07.002

Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and distant metastases. To date few articles regarding chemotherapy for metastatic disease have been reported, thus feasible chemotherapy is not well established. Cetuximab is a monoclonal antibody for epithelial growth factor receptor (EGFR), which has great efficacy for head and neck squamous cell carcinoma due to EGFR signaling pathway blockage. Because BSCC also highly expresses EGFR, cetuximab may be effective for BSCC. We report here a first case of recurrent BSCC in the ethmoid sinus with intracranial extension treated with cetuximab-based chemotherapy, which revealed great response in a 40-year-old man. Positron emission tomography (PET) revealed no lymph node or distant metastasis. The patient underwent chemoradiotherapy 66 Gy in 33 fractions with triweekly 100 mg/m2 cisplatin. However, 12 weeks after treatment completion PET revealed a residual tumor at the primary cancer site. Combination therapy with weekly paclitaxel and cetuximab was started, and complete response was observed 2 months from treatment initiation. The patient has maintained complete response for 32 months, and no tumor regrowth has been observed.

リンク情報
DOI
https://doi.org/10.1016/j.anl.2020.07.002
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32684403
ID情報
  • DOI : 10.1016/j.anl.2020.07.002
  • PubMed ID : 32684403

エクスポート
BibTeX RIS